← Back to Search

Selective Relaxant Binding Agent

Group "S" for Sugammadex for Neuromuscular Blockade (SUGANEO Trial)

Phase 4
Waitlist Available
Led By Philippe PR Richebé, MD PhD
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Undergoing general anesthesia with rocuronium induced NMB
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 15 minutes until discharge from pacu, up to 2 hours
Awards & highlights

SUGANEO Trial Summary

This trial will compare two methods of reversing muscle-blocking drugs used in surgery.

SUGANEO Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are receiving general anesthesia that includes the use of rocuronium to induce neuromuscular blockade.

SUGANEO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 15 minutes until discharge from pacu, up to 2 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 15 minutes until discharge from pacu, up to 2 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time for recovery from moderate NMB
Secondary outcome measures
Cost of reversal agent
Incidence of critical respiratory event
Incidence of reoccurrence of NMB
+12 more

SUGANEO Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group "S" for SugammadexExperimental Treatment1 Intervention
Sugammadex 0.5 mg.kg-1 IV will be performed at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
Group II: Group "N" for Standard reversalActive Control1 Intervention
Standard reversal of 50 µg.kg-1 neostigmine (up to a maximum dose of 5mg) and 7 µg.kg-1 glycopyrrolate at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sugammadex
2017
Completed Phase 4
~3410

Find a Location

Who is running the clinical trial?

Ciusss de L'Est de l'Île de MontréalLead Sponsor
68 Previous Clinical Trials
5,165 Total Patients Enrolled
1 Trials studying Neuromuscular Blockade
50 Patients Enrolled for Neuromuscular Blockade
Philippe PR Richebé, MD PhDPrincipal InvestigatorCIUSSS Est de l'île de Montréal
5 Previous Clinical Trials
262 Total Patients Enrolled

Media Library

Sugammadex (Selective Relaxant Binding Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05718934 — Phase 4
Neuromuscular Blockade Research Study Groups: Group "N" for Standard reversal, Group "S" for Sugammadex
Neuromuscular Blockade Clinical Trial 2023: Sugammadex Highlights & Side Effects. Trial Name: NCT05718934 — Phase 4
Sugammadex (Selective Relaxant Binding Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05718934 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has regulatory approval been granted to the use of Sugammadex in Group "S"?

"Sugammadex has been approved, so its safety rating stands at 3."

Answered by AI

Are there any remaining slots in this trial for potential participants?

"Affirmative. The clinical trial's information on the clinicaltrials.gov website attests to its current recruitment status, which began on November 8th 2022 and was most recently updated on January 30th 2023. 144 patients are being sought from one medical location."

Answered by AI

What is the current size of the participant pool for this clinical experiment?

"Affirmative. Clinicaltrials.gov hosts information which attests to the fact that this medical experiment, initiated on November 8th 2022, is actively looking for participants. 144 patients need to be sourced from a single clinical centre."

Answered by AI

Who else is applying?

What state do they live in?
Quebec
What site did they apply to?
CIUSSS de l'Est de l'Ile de Montreal
What portion of applicants met pre-screening criteria?
Met criteria
~62 spots leftby Mar 2025